HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
First-in-class KRAS-payload leveraging synchronized EGFR inhibition First-in-class KRAS-payload leveraging synchronized EGFR inhibition
First-in-class KRAS-payload leveraging synchronized EGFR inhibition First-in-class KRAS-payload leveraging synchronized EGFR inhibition